Biocon Biologics Expands U.S. Insulin Market Reach with Civica Partnership

New updates have been reported about Biocon Biologics (PC:BICON)

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced an expansion of its strategic collaboration with Civica, Inc. to include the distribution of a new Insulin Glargine medicine in the United States. This agreement positions Biocon Biologics as a key player in providing affordable insulin solutions to the 38.4 million Americans living with diabetes. Under this multi-year agreement, Biocon Biologics will manufacture and supply Insulin Glargine to Civica, which will then commercialize the product under a private label arrangement. This collaboration allows Biocon Biologics to maintain its direct commercialization of its FDA-approved Insulin Glargine-yfgn while leveraging Civica’s distribution channels to reach underserved populations, particularly in California under the CalRx brand. The agreement does not involve any technology transfer, ensuring that Biocon Biologics retains intellectual property rights and marketing authorization for Insulin Glargine. This move builds on a previous partnership where Biocon Biologics supplied Insulin Aspart to Civica for U.S. manufacturing. Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the company’s commitment to expanding access to high-quality, affordable insulins in the U.S. and globally. The partnership aligns with Biocon Biologics’ mission to enhance patient access through strategic collaborations. Civica’s CEO, Ned McCoy, highlighted the significance of this partnership in achieving their goal of providing insulin at a transparent low price. As Biocon Biologics continues to expand its presence in the U.S. market, this collaboration marks a significant step in addressing the needs of diabetic patients by offering more treatment options.